Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of CD5024 1% Cream Versus Metronidazole 0.75% Cream in Subjects With Papulopustular Rosacea Over 16 Weeks Treatment, Followed by a 36-week Extension Period.

NCT01493947 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.

NCT NCT01493947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01493947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of CD5024 1% Cream Versus Metronidazole 0.75% Cream in Subjects With Papulopustular Rosacea Over 16 Weeks Treatment, Followed by a 36-week Extension Period.
Lead sponsor
Galderma R&D
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2012
Completion date
December 31, 2013
Enrollment
962 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

papulopustular rosacea